转自：成都日报锦观 以精准服务促发展 以项目攻坚开新局 全市各级各部门认真学习贯彻市委经济工作会议精神 近期召开的市委经济工作会议为成都"十五五"开局之年经济工作指明了方向、明确了路径、凝聚起共 识。随着学习贯彻会议精神的持续推进，如何将战略部署转化为区域高质量发展的生动实践，成为全市 各级各部门谋划"十五五"开局的关键。一股以"服务提质"激发动能、以"项目攻坚"筑牢根基的实干热潮 正在涌现。 用心做好涉企服务 在四川成都双流经开区，被称为"镇园之宝"的核药龙头企业纽瑞特医疗科技，正聚焦于技术攻坚与产业 落地"双线突进"。"目前，三大重点核药产品已进入临床阶段，实现跨越式增长。"纽瑞特加速器核素及 药物部研发总监介绍。眼下，双流正加快建设具有天府特质、空港气质、公园品质的"智造航空港、幸 福公园城"，"一企一策"精准服务，从项目落地到资质办理，为企业提供全流程支持。同时，双流积极 落实创新药临床研究最高700万元阶段奖励、简化审评审批流程等政策红利，为企业全力冲刺保驾护 航。 在抓项目促投资上"强突破" 推动产业载体迭代升级 围绕贯彻落实会议精神，彭州全市上下将集中精力抓好大事要事，聚焦重点"强突破"，全力确 ...

Core Insights - The approval of GPN01530 for clinical trials in the U.S. marks a significant milestone for the company in the field of innovative pharmaceuticals, particularly in targeting fibroblast activation protein (FAP) for solid tumors [1] - GPN01530 is positioned as a potential game-changer in the diagnosis and treatment of solid tumors, with the ability to reshape the treatment landscape and provide new hope for patients globally [1][7] Group 1: Product and Technology - GPN01530 is not just another innovative nuclear drug; its unique application prospects and technological breakthroughs make it a core competitive asset for the company in the nuclear medicine sector [2] - The drug has shown superior performance in preclinical studies, demonstrating rapid tumor targeting, higher tumor uptake, and better pharmacokinetic properties compared to other FAP ligands [2][3] - GPN01530 has the potential to replace the current standard, 18F-FDG, in the market, setting a new benchmark for FAP-targeted drugs [2] Group 2: Market Potential - FAP is recognized as a promising target in nuclear medicine, with a high expression rate in 90% of epithelial tumors, making it suitable for various cancer types [3][4] - The global cancer incidence is projected to rise from 19.3 million in 2020 to 24.6 million by 2030, leading to an expanding drug market, with estimates suggesting a market size exceeding $200 billion in the U.S. by 2030 [4] - The compound is expected to benefit over ten million patients globally, significantly enhancing the standard of care for solid tumors [7] Group 3: Company Strategy and Globalization - The company has established a comprehensive global layout in the nuclear medicine industry, covering research, production, distribution, and sales [8] - With a robust pipeline of 16 innovative products in the registration phase, the company is one of the leaders in the nuclear medicine sector, particularly in the anti-tumor domain [8][11] - The recent establishment of a state-of-the-art production facility in Chengdu enhances the company's capability to meet global demand and supports its strategic goal of a fully integrated nuclear medicine supply chain [11][13] Group 4: Future Outlook - The company aims to leverage the "dual filing" international registration strategy to advance GPN01530's global development and registration efforts [14] - This approach not only enhances the company's clinical registration capabilities abroad but also allows for the integration of clinical trial experiences from mature markets back into domestic practices [14] - The successful development of GPN01530 could set a precedent for other Chinese innovative drugs to enter global markets, contributing to the global fight against cancer [14]

Group 1: Industry Developments - China's medical isotope self-sufficiency has made significant progress with the successful development of a complete eco-friendly industrial chain for iodine-131, including precursor preparation, reactor irradiation, and nuclear drug research [1] - The global nuclear medicine market is projected to reach nearly $39 billion by 2032, indicating strong growth potential in the sector [1] - The number of approved radiotherapy devices in China has exceeded 90, with over 70% being domestically produced, marking a shift from reliance on imports [2] Group 2: Company Highlights - China Tongyuan (01763) has signed a commercial cooperation agreement with Novartis for the radioligand therapy drug, providing a new treatment option for advanced prostate cancer patients [3] - Yuan Da Pharmaceutical (00512) has 15 innovative nuclear drugs in the registration phase, with a significant revenue increase of nearly 106% in its nuclear medicine segment, driven by the performance of its yttrium-90 microsphere injection [3] - Sidi Pharmaceutical (01244) has completed the first patient dosing of its radiolabeled drug, 177Lu-PSMA-3D1015, which aims to provide a safer and more effective treatment for metastatic castration-resistant prostate cancer [4]

Group 1: Industry Developments - China's medical isotope self-sufficiency has made significant progress, with the establishment of a complete eco-friendly autonomous industrial chain for iodine-131 production, including precursor preparation, reactor irradiation, and nuclear drug development [1] - The global nuclear medicine market is projected to reach nearly $39 billion by 2032, indicating strong growth potential in the sector [1] - The number of approved radiotherapy devices in China has exceeded 90, with over 70% being domestically produced, marking a shift from reliance on imports [2] Group 2: Company Updates - China National Nuclear Corporation's subsidiary, Atomic High-Tech Co., has signed a commercial cooperation agreement with Novartis for the radioligand therapy drug, which is the first approved targeted PSMA therapy for advanced prostate cancer in China [3] - Yuan Da Pharmaceutical has 15 innovative nuclear drugs in the R&D registration phase, with a significant revenue increase in its nuclear medicine segment, achieving approximately HKD 420 million in revenue, a year-on-year growth of nearly 106% [3] - Sillod Medical has completed the first patient dosing in a study for its radiolabeled drug, 177Lu-PSMA-3D1015, aimed at treating metastatic castration-resistant prostate cancer, positioning it as a potential best-in-class product [4]

Group 1: Medical Isotope Production - China National Nuclear Corporation (CNNC) has successfully developed a complete technology chain for the irradiation preparation of iodine-131, enhancing the self-sufficiency of medical isotopes in China [1] - The technology includes the preparation of precursor isotopes, reactor irradiation, and nuclear drug development, forming an environmentally friendly and autonomous industrial chain [1] - The successful production of high-purity tellurium-130 isotopes with over 99% abundance fills a gap in the domestic large-scale preparation of high-purity enriched tellurium isotopes [1] Group 2: Radiation Therapy Equipment and Drug Development - As of 2024, over 90 radiotherapy devices have been approved by the National Medical Products Administration, with more than 70% being domestic brands, significantly reducing reliance on imported equipment [2] - The development of new radiopharmaceuticals has accelerated, with over 200 pipelines entering clinical trials, introducing new isotopes like lutetium-177 and yttrium-90 for more precise cancer treatment options [2] Group 3: Corporate Transactions and Financial Updates - WuXi AppTec has completed the sale of its subsidiary, expecting a post-tax net profit of approximately 960 million yuan, which accounts for over 10% of the company's latest audited net profit attributable to shareholders [5][6] - Guolian Minsheng has terminated a 480 million yuan fund establishment transaction, with no adverse effects on the company's finances or shareholder rights [7] - Morning Paper Industry plans to sell all shares of a target company for 3.336 billion yuan [10] Group 4: New Technologies and Innovations - GAC Group's flying car, GOVY AirCab, has entered the airworthiness certification stage and is expected to be mass-produced by 2026, aiming to create a new mode of transportation that integrates air and ground travel [17] - China Tongyuan has signed a commercial cooperation agreement with Novartis for the radiopharmaceutical product, providing a new treatment option for advanced prostate cancer patients [18]

此次签约既是对双方前期合作成果的阶段性总结，更是高校与企业协同推动科研成果转化为国家战略生 产力的关键起点。当前核医学产业正迎来黄金发展期，原子高科凭借深厚行业积淀与鲜明产业特色，已 成为领域内核心力量。未来双方将以产学研协作为纽带，加速核心成果临床转化、搭建人才共育快车 道，参与全球核药新技术竞争，为我国核医学事业高质量发展筑牢根基。 中国同辐(01763)发布公告，2025年12月10日，原子高科股份有限公司(本公司旗下一间于全国中小企业 股份转让系统上市的附属公司)与北京师范大学在北京举办科技成果转化签约暨产学研合作交流会，共 同签署了氟[18F]贝他嗪项目《专利转让协议》与《产学研合作协议》。 氟[18F]贝他嗪是北京师范大学崔孟超教授团队与原子高科合作研发的成果，为具有完全自主知识产权 的一类新药，主要用于阿尔茨海默病的早期诊断。该药物在临床应用中表现出脑白质非特异性摄取显著 降低的特点，优于已获FDA批准的同类产品。 ...

智通财经APP讯，中国同辐(01763)发布公告，2025年12月10日，原子高科股份有限公司(本公司旗下一 间于全国中小企业股份转让系统上市的附属公司)与北京师范大学在北京举办科技成果转化签约暨产学 研合作交流会，共同签署了氟[F]贝他嗪项目《专利转让协议》与《产学研合作协议》。 此次签约既是对双方前期合作成果的阶段性总结，更是高校与企业协同推动科研成果转化为国家战略生 产力的关键起点。当前核医学产业正迎来黄金发展期，原子高科凭借深厚行业积淀与鲜明产业特色，已 成为领域内核心力量。未来双方将以产学研协作为纽带，加速核心成果临床转化、搭建人才共育快车 道，参与全球核药新技术竞争，为我国核医学事业高质量发展筑牢根基。 氟[F]贝他嗪是北京师范大学崔孟超教授团队与原子高科合作研发的成果，为具有完全自主知识产权的 一类新药，主要用于阿尔茨海默病的早期诊断。该药物在临床应用中表现出脑白质非特异性摄取显著降 低的特点，优于已获FDA批准的同类产品。 ...

格隆汇12月11日丨中国同辐(01763.HK)公告，以下公告的中文原稿由中国同辐股份有限公司旗下一间于 全国中小企业股份转让系统上市的附属公司，原子高科股份有限公司(股份代号：430005)于中国境内发 布。 氟[F]贝他嗪是北京师范大学崔孟超教授团队与原子高科合作研发的成果，为具有完全自主知识产权的 一类新药，主要用于阿尔茨海默病的早期诊断。该药物在临床应用中表现出脑白质非特异性摄取显著降 低的特点，优于已获FDA批准的同类产品。 此次签约既是对双方前期合作成果的阶段性总结，更是高校与企业协同推动科研成果转化为国家战略生 产力的关键起点。当前核医学产业正迎来黄金发展期，原子高科凭借深厚行业积淀与鲜明产业特色，已 成为领域内核心力量。未来双方将以产学研协作为纽带，加速核心成果临床转化、搭建人才共育快车 道，参与全球核药新技术竞争，为我国核医学事业高质量发展筑牢根基。 2025年12月10日，原子高科股份有限公司(以下简称"原子高科")与北京师范大学(以下简称"北师大")在 北京举办科技成果转化签约暨产学研合作交流会，共同签署了氟[18F]贝他嗪项目《专利转让协议》与 《产学研合作协议》。 ...

Core Insights - The company, China General Nuclear Power Technology (CGN), announced on November 3 that its medical isotope production is a fundamental raw material for the development of nuclear pharmaceuticals, positioning it in the upstream segment of the nuclear medicine industry [2] Group 1 - The core production equipment for the isotope business, including accelerator main devices and process hot rooms, has been delivered and is currently undergoing installation and debugging [2] - The company plans to commence production in 2026 [2]

Core Viewpoint - China Tongru (01763) experienced a significant stock price increase of over 7% during trading, attributed to the launch of high-purity 13CO gas and urea products, marking a shift towards self-sufficiency in the medical stable isotope carbon sector [1] Company Overview - China Tongru is a specialized company under China National Nuclear Corporation, focusing on nuclear technology applications, including the development, production, and sales of nuclear medicine, radiation source products, and related services [1] - The company has established a comprehensive layout in the nuclear medicine field, with a network of 37 medical centers and 7 R&D production bases by December 31, 2024, positioning itself as a leader in China's nuclear medicine sector [1] Industry Impact - The launch of high-purity 13CO gas and urea products signifies China's ability to break free from reliance on imported materials for urea breath diagnostic agents, achieving full control over the entire industry chain from key raw materials to end products [1] - This development enhances the company's status as a leading enterprise capable of managing the complete supply chain for breath test products in the medical stable isotope carbon field [1]